As Eli Lilly and Novo Nordisk compete to capture share of the weight-loss drug market, Ajaykumar D. Rao, MD, MMSc, FACP, Chief of the Section of Endocrinology, Diabetes and Metabolism at the Lewis Katz School of Medicine at Temple University, told Medscape that clinicians and patients may be the ultimate winners.